LENZ Therapeutics, Inc. (LENZ)
4.60
-0.08
(-1.71%)
USD |
NASDAQ |
Aug 24, 16:00
4.60
0.00 (0.00%)
After-Hours: 20:00
LENZ Therapeutics Max Drawdown (5Y) : 97.31% for July 31, 2026
Max Drawdown (5Y) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| July 31, 2026 | 97.31% |
| June 30, 2026 | 97.28% |
| May 31, 2026 | 96.71% |
| April 30, 2026 | 95.90% |
| March 31, 2026 | 95.90% |
| February 28, 2026 | 94.27% |
| January 31, 2026 | 93.98% |
| Date | Value |
|---|---|
| December 31, 2025 | 93.98% |
| November 30, 2025 | 93.98% |
| October 31, 2025 | 93.98% |
| September 30, 2025 | 93.98% |
| August 31, 2025 | 93.98% |
| July 31, 2025 | 93.98% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| Ocular Therapeutix, Inc. | 90.94% |
| Enveric Biosciences, Inc. | 100.00% |
| Liquidia Corp. | 93.87% |
| Aquestive Therapeutics, Inc. | 96.68% |
| Impact BioMedical, Inc. | -- |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -57.72 |
| Beta (5Y) | 0.6489 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 68.29% |
| Historical Sharpe Ratio (5Y) | -0.7577 |
| Historical Sortino (5Y) | -1.150 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 38.33% |